The Orogenta® Technology enables to achieve zero-order release MUPS tablets coating of the embedded multiparticulates. Some key benefits are:

 

• Zero-order drug release tablets
• No coating of pellets -> Simplified manufacturing process robust production process; good for tableting-> no rupture or damage of coating during tablet compression
• Various formulation options
• Overcoming patent protection – patent circumvention
• Precise control of drug release kinetics: Capabilities include extended and modified release options for new formulations or product life cycle management: Ability to match existing products for simplified 505(b)(2) FDA pathway for speed to market!

 For more Information please get in touch via email

 

Sponsored Content